hotspot -WSS

hotspot

author：explore 2025-09-14 18:30:22 - browse：42

Adam's take main illustration — Molly Ferguson/STAT

CHICAGO — Something is off about the way Novartis is talking about pelabresib, its newly acquired and costly treatment for myelofibrosis. I suspect the Swiss pharma giant’s previously stated plan to submit a marketing application to the Food and Drug Administration this year has been blocked.

I’m not just speculating wildly. It’s looking increasingly likely that the $3 billion purchase of MorphoSys to acquire pelabresib — a deal pushed hard by top Novartis executive strategist Ronny Gal over some internal dissent — has run into serious trouble just days after the closing.

On Sunday evening, Novartis Chief Medical Officer Shreeram Aradhye, speaking at the company’s ASCO investor event here in Chicago, offered this response to an analyst who asked about pelabresib.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus in-depth analysis, newsletters, premium events, and networking platform access.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Guidelines to prevent youth baseball injuries need more muscle
Next article： Medical leaders decry Supreme Court decision on affirmative action

WSS

Positive childhood experiences can help future health

Affirmative action in medical school literally saved lives

In age of alternative facts, a scholarly course on calling out crap

Novavax promises a turnaround & Lilly roils the obesity market

DIEP, the 'gold standard' of breast reconstruction, is under threat

FDA approval of Sarepta Duchenne genetic therapy gives me hope

explore

hotspot

This article is exclusive to STAT+ subscribers

Unlock this article — plus in-depth analysis, newsletters, premium events, and networking platform access.

focus

Wildfire smoke exposes gaps in outdoor worker protections

23andMe had bad news about my health. I wish a person had delivered it

New Eli Lilly Alzheimer’s data poses Medicare coverage conundrum

Medicare proposal to cover medical devices draws a mixed reaction

Wildfire smoke exposes gaps in outdoor worker protections

FDA approval of Sarepta Duchenne genetic therapy gives me hope

Supreme Court strikes down use of affirmative action

Leading voice in opioid treatment defends methadone clinic system

Affirmative action in medical school literally saved lives

Indiana Supreme Court upholds abortion ban, says state constitution gives only limited protections

focus

As demand for Covid shots wanes, Moderna seeks its next success

SCOTUS questions limit to govt efforts to fight misinformation

Methadone treatment changes are coming. Do they go far enough?

Asbestos, a deadly carcinogen, banned by EPA

Stop the failed accountable care organization experiment

Orchard's therapy for neuron disease in children wins FDA approval

explore

explore

hotspot

Wikipedia